GlassScriptPhysician profile
Aswathi Chandran
NPI 1578948956
$5,757.11
in general payments reported to CMS, 2019-2025
32 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.29 · 2020: $99.00 · 2021: $808 · 2022: $1,563 · 2023: $1,162 · 2024: $1,258 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Education: $34.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.60 |
| Education | $34.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,280.84 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $518.63 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $370.51 | 2020-2024 | Stelara, Remicade, Simponi |
| Gilead Sciences, INC. | $271.64 | 2021-2024 | |
| Genzyme Corporation | $225.65 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $180.27 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $172.69 | 2024 | Voquezna |
| Pfizer INC. | $161.17 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.80 | 2021-2024 | Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $123.77 | 2021-2025 | |
| Lilly USA, LLC | $122.44 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $107.49 | 2021-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $106.60 | 2021 | |
| Boston Scientific Corporation | $93.75 | 2021 | |
| Celgene Corporation | $91.19 | 2022-2023 | Zeposia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aries Pharmaceuticals, INC. | $90.29 | 2019 | |
| Celltrion USA INC. | $86.80 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $76.78 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $56.40 | 2021-2024 | Sucraid, Sucraid |
| Organon LLC | $55.76 | 2022 | |
| Erbe USA INC | $54.93 | 2021 | |
| Daiichi Sankyo INC. | $54.56 | 2021-2022 | |
| Amgen INC. | $48.58 | 2022-2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $42.35 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $39.67 | 2024-2025 | Suflave |
| Ambu INC. | $36.63 | 2021 | |
| Dynavax Technologies Corporation | $35.87 | 2021-2022 | |
| Redhill Biopharma INC. | $29.94 | 2022 | |
| Evoke Pharma, INC. | $24.07 | 2023 | Gimoti |
| Alfasigma USA, INC. | $17.87 | 2021 | |
| Aimmune Therapeutics, INC. | $14.05 | 2024 | |
| Medtronic, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aswathi Chandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.